000			03848nam a22004335i 4500
999			_c368674 _d368674 _x1
001			368674
003			ES-MaUEC
005			20230102121757.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			211219s2022 sz | s |||| 0|eng d
020			_a9783030878498
024	7		_a10.1007/978-3-030-87849-8 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC271 .I45 _b2022 EB
245	1	0	_aGene and Cellular Immunotherapy for Cancer _cedited by Armin Ghobadi, John F. DiPersio
250			_aFirst edition 2022
264		1	_aCham _bSpringer International Publishing, _c2022
300			_a1 recurso en línea (X, 378 páginas) _b29 ilustraciones, 28 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
490	1		_aCancer Drug Discovery and Development _x2196-9914
505	0		_aThe History of Cellular Therapies -- Basics of Immunity -- Biology of CAR T cells -- Cell types used for CAR generation -- Combination therapeutics with CART cell therapy -- Safety switches used for cellular therapies -- Off-the-shelf CAR-T -- Manufacturing of CAR-T Cells: the Assembly Line -- Navigating Regulations in Gene and Cell Immunotherapy -- Bringing CAR-T to the Clinic -- CAR T-Cell Complications -- Mechanisms of Resistance and Relapse after CAR T cell therapy -- Tumor infiltrating lymphocytes (TIL): from bench to bedside -- T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic -- Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside -- Biology of NK cells and NK cells in clinic -- Biology and Clinical Evaluation of T/NK Cell Engagers -- Roadmap for Starting an Outpatient Cellular Therapy Program -- Index.
520			_aClinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.
988			_aSpringer_Medicine_2022
650		7	_2embne _9348509 _aCáncer _xInmunoterapia
700	1		_aGhobadi, Armin _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aDiPersio, John F. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030878481
776	0	8	_iPrinted edition: _z9783030878504
776	0	8	_iPrinted edition: _z9783030878511
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-87849-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE _n0
998			_b04/2022 _dz _eh _zSI